First Page | Document Content | |
---|---|---|
Date: 2018-04-10 18:00:06 | Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (Pegsiticase) with SVPRapamycin Enables Sustained Reduction of Serum Uric Acid Levels by Mitigating Formation of Anti-DAdd to Reading ListSource URL: selectabio.comDownload Document from Source WebsiteFile Size: 1,35 MBShare Document on Facebook |